These and other findings have suggested that targeting the Nrf2 pathway may be a new cancer therapy. Researchers have tried to identify molecules activators of NrF2 as chemoprevention ROS-dependent carcinogenesis, while others have focused on identifying NrF2 inhibitors to increase sensitivity of cancer cells to chemotherapy. This evidence concerns the gene NFE2L2 and cancer.